Agency Information Collection Activities; Proposed Collection; Comment Request; Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-to-Consumer Prescription Drug Ads, 67172-67174 [2014-26698]
Download as PDF
<![CDATA[
67172
Federal Register / Vol. 79, No. 218 / Wednesday, November 12, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Trafficking Victims Tracking
System.
OMB No.: 0970—NEW.
Description: The Trafficking Victims
Protection Act, Public Law 106–386,
Division A, 114 Stat. 1464 (2000),
requires the Department of Health and
Human Services (HHS) to certify adult
alien (‘‘foreign’’) victims of severe forms
of trafficking in persons (‘‘human
trafficking’’) who are willing to assist
law enforcement in the investigation
and prosecution of human trafficking,
unless unable to cooperate due to
physical or psychological trauma, and
who have either made a bona fide
application for T nonimmigrant status
that has not been denied or been granted
Continued Presence (CP) from the U.S.
Department of Homeland Security
(DHS). Issued by the Office of Refugee
Resettlement (ORR) within the HHS
Administration for Children and
Families, certification letters grant adult
foreign victims of human trafficking
access to federal and state benefits and
services to the same extent as refugees.
In general, ORR initiates the
certification process when it receives a
notice from DHS that DHS has granted
a foreign victim of trafficking CP or T
nonimmigrant status, or has determined
an application for T nonimmigrant
status is bona fide. To issue certification
letters, it is necessary for ORR to collect
information from a victim’s
representative, such as an attorney, case
manager, or law enforcement victim
specialist, including an address to send
the letter. In line with other ORR AntiTrafficking in Persons Program
activities, ORR may ask if the victim is
in need of a service provider and the
current location (city, state) of the
victim, and refer the victim to an
appropriate service provider in his or
her area, if requested. ORR will also ask
about the victim’s language and urgent
concerns, such as medical care or
housing, and transmit this information
to the service provider.
Finally ORR collects information,
such as the victim’s sex and the type of
human trafficking the victim
experienced, to provide to Congress in
an annual report on U.S. Government
activities to combat trafficking that is
prepared by the U.S. Department of
Justice. Congress requires HHS and
other appropriate Federal agencies to
report, at a minimum, information on
the number of persons who received
benefits or other services under
subsections (b) and (f) of section 7105 of
Title 22 of the U.S. Code, the TVPA, in
connection with programs or activities
funded or administered by HHS. HHS
includes in these annual reports
additional information about the victims
that it collects when assisting each
victim to obtain certification or
eligibility. ORR will store this
information and any other details
regarding the victim’s case in the
Trafficking Victims Tracking System
(TVTS) on ORR’s secure database. Other
details maintained in the victim’s file
may include ORR staff actions, referrals,
and notes regarding the victim’s interest
in receiving services. Maintaining
victim records on TVTS will ensure
efficient service for victims, allow ORR
staff to track victims’ progress toward
certification, verify their eligibility for
benefits, and organize information for
reporting to Congress.
The TVTS also includes information
about foreign victims of trafficking and
potential victims who were minors
when an eligibility letter was sought
from ORR. Information about these
individuals is collected pursuant to an
OMB-approved collection, OMB Control
Number 0970–0362.
In January 2011, the Archivist of the
United States approved an Electronic
System Schedule for the disposition of
TVTS records.
Respondents: Respondents can
include attorneys, legal representatives,
social service providers, case managers,
and volunteers acting on behalf of the
adult foreign victim of trafficking.
ANNUAL BURDEN ESTIMATES
Number of
respondents
TKELLEY on DSK3SPTVN1PROD with NOTICES
Estimated Total Annual Burden
Hours: 80.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. All requests should be
identified by the title of the information
collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
VerDate Sep<11>2014
17:55 Nov 10, 2014
Jkt 235001
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
800
Instrument
1
.1
80
proposed information collection should
be sent directly to the following:
Office of Management and Budget,
Paperwork Reduction Project, Email:
OIRA_SUBMISSION@OMB.EOP.GOV,
Attn: Desk Officer for the
Administration for Children and
Families.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2014–26723 Filed 11–10–14; 8:45 am]
BILLING CODE 4184–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1794]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Impact of Ad
Exposure Frequency on Perception
and Mental Processing of Risk and
Benefit Information in Direct-toConsumer Prescription Drug Ads
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
SUMMARY:
Frm 00017
Fmt 4703
Sfmt 4703
E:\FR\FM\12NON1.SGM
12NON1
Federal Register / Vol. 79, No. 218 / Wednesday, November 12, 2014 / Notices
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
research entitled, ‘‘Impact of Ad
Exposure Frequency on Perception and
Mental Processing of Risk and Benefit
Information in DTC Prescription Drug
Ads.’’ This project will examine the
effects of variation in ad exposure
frequency on perception and mental
processing of risk and benefit
information in direct-to-consumer (DTC)
prescription drug ads.
DATES: Submit either electronic or
written comments on the collection of
information by January 12, 2015.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
67173
repeat messages is varied (Ref. 2).
Generally, it has been argued that first
exposure to an ad results in attention,
second exposure affects learning of the
advertised message, and third and
subsequent exposures reinforce the
learning effects of the second exposure
(Ref. 3). To our knowledge, the literature
concerning ad exposure frequency has
not been extended to include specific
attention to prescription drug ads.
Prescription drug ads are unique in that
they are required to provide both benefit
and risk information whereas other ad
types tend to include only benefit
information. The Office of Prescription
Drug Promotion plans to examine the
effects of variation in ad exposure
frequency on perception and mental
processing of risk and benefit
information in DTC prescription drug
ads through empirical research.
The main study will be preceded by
up to two pretests designed to delineate
the procedures and measures used in
the main study. Across pretests and the
main study, participants will be
individuals who have been diagnosed
with seasonal allergies. All participants
will be 18 years of age or older. We will
exclude individuals who work in
healthcare or marketing settings because
their knowledge and experiences may
not reflect those of the average
consumer. Participants will be recruited
in one of two geographic locations
(Washington, DC and Raleigh-Durham,
NC) for in-person administration of
protocols.
The experimental design is
summarized in Table 1. Participants
will be randomly assigned to view a
prescription drug ad one, three, or six
times as part of clutter reels embedded
in a 42 minute TV program. They will
then answer preprogrammed survey
questions on laptops. Preliminary
measures are designed to assess
perception, memory, judgments about
the ad, intentions to use the medication
advertised, and possible moderators of
effects, such as need for cognition and
demographics. The questionnaire is
available upon request. Participation is
estimated to take up to 2 hours.
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Impact of Ad Exposure Frequency on
Perception and Mental Processing of
Risk and Benefit Information in DTC
Prescription Drug Ads—(OMB Control
Number 0910—NEW)
Section 1701(a)(4) of the Public
Health Service Act (42 U.S.C.
300u(a)(4)) authorizes FDA to conduct
research relating to health information.
Section 1003(d)(2)(C) of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 393(b)(2)(c))
authorizes FDA to conduct research
relating to drugs and other FDA
regulated products in carrying out the
provisions of the FD&C Act.
In a typical promotional campaign,
consumers may be exposed to a DTC
prescription drug ad any number of
times. Perceptual and cognitive effects
of increased ad exposure frequency have
been studied extensively using non-drug
ads. For instance, one study
demonstrated that a commercial
message repeated twice generates better
recall than a message broadcast only
once (Ref. 1). Another study
demonstrated that increased ad
exposures improve product attitudes
and recall for product attributes,
particularly when the substance of the
TABLE 1—EXPERIMENTAL DESIGN
TKELLEY on DSK3SPTVN1PROD with NOTICES
42 Minute television show, clutter reel No.
Experimental Arm No.
1
1 (views ad 1 time) ...........
2 (views ad 3 times) .........
3 (views ad 6 times) .........
VerDate Sep<11>2014
2
3
4
5
............................
Mock DTC ad ....
Mock DTC ad ....
............................
............................
Mock DTC ad ....
............................
............................
Mock DTC ad ....
............................
Mock DTC ad ....
Mock DTC ad ....
............................
............................
Mock DTC ad ....
17:55 Nov 10, 2014
Jkt 235001
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
E:\FR\FM\12NON1.SGM
12NON1
6
Mock DTC ad.
Mock DTC ad.
Mock DTC ad.
67174
Federal Register / Vol. 79, No. 218 / Wednesday, November 12, 2014 / Notices
To examine differences between
experimental conditions, we will
conduct inferential statistical tests such
as analysis of variance. With the sample
size described in the following table, we
will have sufficient power to detect
small-to-medium sized effects in the
main study.
FDA estimates the burden of this
collection of information as follows:
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Number of
responses per
respondent
Total annual
respondents
Average burden per
response
Total hours
Pretest 1 screener completes (assumes 10% eligible)
Pretest 2 screener completes (assumes 10% eligible)
Number of main study screener completes (assumes
10% eligible).
Pretest 1 completes .....................................................
Pretest 2 completes .....................................................
Number of completes, main study ..............................
4,150
4,150
620
1
1
1
4,150
4,150
620
0.08 (5 minutes) .....
0.08 (5 minutes) .....
0.08 (5 minutes) .....
332
332
50
420
420
620
1
1
1
420
420
620
2 .............................
2 .............................
2 .............................
840
840
1240
Total ......................................................................
........................
........................
........................
................................
3,634
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
References
The following references have been
placed on display in the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and are available
electronically at https://
www.regulations.gov.
1. Singh, S. N., D. Linville, and A. Sukhdial,
‘‘Enhancing the Efficacy of Split ThirtySecond Television Commercials: An
Encoding Variability Application,’’
Journal of Advertising, 24, pp. 13–23
(1995).
2. Haugtvedt, C. P., et al., ‘‘Advertising
Repetition and Variation Strategies:
Implications for Understanding Attitude
Strength,’’ Journal of Consumer
Research, 21, pp. 176–189 (1994).
3. Naples, M. J., ‘‘Effective Frequency: Then
and Now,’’ Journal of Advertising
Research, 37, pp. 7–12 (1997).
Dated: November 5, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–26698 Filed 11–10–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
TKELLEY on DSK3SPTVN1PROD with NOTICES
[Docket No. FDA–2013–F–1539]
DSM Nutritional Products; Food
Additive Petition (Animal Use);
Ethoxyquin; Environmental
Assessment
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA) is announcing the
availability of an environmental
SUMMARY:
VerDate Sep<11>2014
17:55 Nov 10, 2014
Jkt 235001
the National Environmental Policy Act
(40 CFR 1501.4(b)), the Agency is
placing the environmental assessment
submitted with the petition that is the
subject of this notice on public display
at the Division of Dockets Management
(see ADDRESSES) for public review and
comment.
ADDRESSES: Submit electronic
Interested persons may submit to the
comments to: https://
Division of Dockets Management (see
www.regulations.gov. Submit written
ADDRESSES) electronic or written
comments to the Division of Dockets
comments regarding this document.
Management (HFA–305), Food and Drug Submit a single copy of electronic
Administration, 5630 Fishers Lane, rm.
comments or two paper copies of any
1061, Rockville, MD 20852.
mailed comments, except that
FOR FURTHER INFORMATION CONTACT:
individuals may submit one paper copy.
Isabel W. Pocurull, Center for Veterinary Comments are to be identified with the
Medicine, Food and Drug
docket number found in brackets in the
Administration, 7519 Standish Pl.,
heading of this document. Received
Rockville, MD 20855, 240–453–6853.
comments may be seen in the Division
SUPPLEMENTARY INFORMATION: In the
of Dockets Management between 9 a.m.
Federal Register of December 23, 2013
and 4 p.m., Monday through Friday.
(78 FR 77384) FDA published notice
FDA will also place on public display
that a food additive petition (FAP) had
any amendments to, or comments on,
been filed by DSM Nutritional Products, the petitioner’s environmental
45 Waterview Blvd., Parsippany, NJ
assessment without further
07054. The petition (FAP 2276)
announcement in the Federal Register.
proposes to amend Title 21 of the Code
If, based on its review, the Agency finds
of Federal Regulations (CFR) in part 573
that an environmental impact statement
Food Additives Permitted in Feed and
Drinking Water of Animals (21 CFR part is not required and this petition results
in a regulation, the notice of availability
573) to provide for the safe use of
of the Agency’s finding of no significant
ethoxyquin as a chemical preservative
in vitamin D formulations, including 25- impact and the evidence supporting that
hydroxyvitamin D3, used in animal food. finding will be published with the
regulation in the Federal Register in
In that document, FDA noted that the
accordance with 21 CFR 25.51(b).
petitioner had requested a categorical
exclusion from preparing an
Dated: November 6, 2014.
environmental assessment or
Bernadette Dunham,
environmental impact statement under
Director, Center for Veterinary Medicine.
21 CFR 25.32(k).
[FR Doc. 2014–26709 Filed 11–10–14; 8:45 am]
Upon further review and request by
BILLING CODE 4164–01–P
FDA, the petitioner has filed an
environmental assessment. To
encourage public participation
consistent with regulations issued under
assessment filed by DSM Nutritional
Products in support of their petition
proposing that the food additive
regulations be amended to provide for
the safe use of ethoxyquin in vitamin D
formulations, including 25hydroxyvitamin D3, used in animal
food.
PO 00000
Frm 00019
Fmt 4703
Sfmt 9990
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 79, Number 218 (Wednesday, November 12, 2014)]
[Notices]
[Pages 67172-67174]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26698]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-1794]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Impact of Ad Exposure Frequency on Perception and
Mental Processing of Risk and Benefit Information in Direct-to-Consumer
Prescription Drug Ads
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
[[Page 67173]]
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on research entitled, ``Impact of Ad Exposure
Frequency on Perception and Mental Processing of Risk and Benefit
Information in DTC Prescription Drug Ads.'' This project will examine
the effects of variation in ad exposure frequency on perception and
mental processing of risk and benefit information in direct-to-consumer
(DTC) prescription drug ads.
DATES: Submit either electronic or written comments on the collection
of information by January 12, 2015.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Impact of Ad Exposure Frequency on Perception and Mental Processing of
Risk and Benefit Information in DTC Prescription Drug Ads--(OMB Control
Number 0910--NEW)
Section 1701(a)(4) of the Public Health Service Act (42 U.S.C.
300u(a)(4)) authorizes FDA to conduct research relating to health
information. Section 1003(d)(2)(C) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 393(b)(2)(c)) authorizes FDA to
conduct research relating to drugs and other FDA regulated products in
carrying out the provisions of the FD&C Act.
In a typical promotional campaign, consumers may be exposed to a
DTC prescription drug ad any number of times. Perceptual and cognitive
effects of increased ad exposure frequency have been studied
extensively using non-drug ads. For instance, one study demonstrated
that a commercial message repeated twice generates better recall than a
message broadcast only once (Ref. 1). Another study demonstrated that
increased ad exposures improve product attitudes and recall for product
attributes, particularly when the substance of the repeat messages is
varied (Ref. 2). Generally, it has been argued that first exposure to
an ad results in attention, second exposure affects learning of the
advertised message, and third and subsequent exposures reinforce the
learning effects of the second exposure (Ref. 3). To our knowledge, the
literature concerning ad exposure frequency has not been extended to
include specific attention to prescription drug ads. Prescription drug
ads are unique in that they are required to provide both benefit and
risk information whereas other ad types tend to include only benefit
information. The Office of Prescription Drug Promotion plans to examine
the effects of variation in ad exposure frequency on perception and
mental processing of risk and benefit information in DTC prescription
drug ads through empirical research.
The main study will be preceded by up to two pretests designed to
delineate the procedures and measures used in the main study. Across
pretests and the main study, participants will be individuals who have
been diagnosed with seasonal allergies. All participants will be 18
years of age or older. We will exclude individuals who work in
healthcare or marketing settings because their knowledge and
experiences may not reflect those of the average consumer. Participants
will be recruited in one of two geographic locations (Washington, DC
and Raleigh-Durham, NC) for in-person administration of protocols.
The experimental design is summarized in Table 1. Participants will
be randomly assigned to view a prescription drug ad one, three, or six
times as part of clutter reels embedded in a 42 minute TV program. They
will then answer preprogrammed survey questions on laptops. Preliminary
measures are designed to assess perception, memory, judgments about the
ad, intentions to use the medication advertised, and possible
moderators of effects, such as need for cognition and demographics. The
questionnaire is available upon request. Participation is estimated to
take up to 2 hours.
Table 1--Experimental Design
--------------------------------------------------------------------------------------------------------------------------------------------------------
42 Minute television show, clutter reel No.
Experimental Arm No. -----------------------------------------------------------------------------------------------------------------------
1 2 3 4 5 6
--------------------------------------------------------------------------------------------------------------------------------------------------------
1 (views ad 1 time)............. .................. .................. .................. .................. .................. Mock DTC ad.
2 (views ad 3 times)............ Mock DTC ad....... .................. .................. Mock DTC ad....... .................. Mock DTC ad.
3 (views ad 6 times)............ Mock DTC ad....... Mock DTC ad....... Mock DTC ad....... Mock DTC ad....... Mock DTC ad....... Mock DTC ad.
--------------------------------------------------------------------------------------------------------------------------------------------------------
[[Page 67174]]
To examine differences between experimental conditions, we will
conduct inferential statistical tests such as analysis of variance.
With the sample size described in the following table, we will have
sufficient power to detect small-to-medium sized effects in the main
study.
FDA estimates the burden of this collection of information as
follows:
Table 2--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent respondents
--------------------------------------------------------------------------------------------------------------------------------------------------------
Pretest 1 screener completes (assumes 10% 4,150 1 4,150 0.08 (5 minutes)......................... 332
eligible).
Pretest 2 screener completes (assumes 10% 4,150 1 4,150 0.08 (5 minutes)......................... 332
eligible).
Number of main study screener completes 620 1 620 0.08 (5 minutes)......................... 50
(assumes 10% eligible).
Pretest 1 completes.......................... 420 1 420 2........................................ 840
Pretest 2 completes.......................... 420 1 420 2........................................ 840
Number of completes, main study.............. 620 1 620 2........................................ 1240
----------------------------------------------------------------------------------------------------------
Total.................................... .............. .............. .............. ......................................... 3,634
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
References
The following references have been placed on display in the
Division of Dockets Management (see ADDRESSES) and may be seen by
interested persons between 9 a.m. and 4 p.m., Monday through Friday,
and are available electronically at https://www.regulations.gov.
1. Singh, S. N., D. Linville, and A. Sukhdial, ``Enhancing the
Efficacy of Split Thirty-Second Television Commercials: An Encoding
Variability Application,'' Journal of Advertising, 24, pp. 13-23
(1995).
2. Haugtvedt, C. P., et al., ``Advertising Repetition and Variation
Strategies: Implications for Understanding Attitude Strength,''
Journal of Consumer Research, 21, pp. 176-189 (1994).
3. Naples, M. J., ``Effective Frequency: Then and Now,'' Journal of
Advertising Research, 37, pp. 7-12 (1997).
Dated: November 5, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-26698 Filed 11-10-14; 8:45 am]
BILLING CODE 4164-01-P
